EHA 2017 | New strategies in AML: checkpoint inhibitors combined with T-cell engagers
Marion Subklewe
• 22 Jun 2017
Through the cytokine secretion of T-Cells, we comprehend an up-regulation of the checkpoint inhibitors. Marion Subklewe, MD, from the LMU-University Hospital, Munich, Germany, believes we can already show how the combination with checkpoint inhibitors of T-cell engagers can enhance efficacy and T-cell proliferation. There have been some very interesting data in the CAR T-Cell field, combining with ibrutinib as an example. Dr Subklewe mentions looking ahead to see if we can implement some of these strategies in acute myeloid leukemia (AML). Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
